Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers, notably multiple myeloma and myelodysplastic syndromes, and is prescribed for adult patients under specialist supervision.

GNH USA supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is used in hematologic oncology to modify disease progression and improve patient outcomes.

- Multiple myeloma (initial therapy): reduces tumor burden and prolongs progression‑free survival when combined with other agents. - Multiple myeloma (maintenance): helps sustain remission after initial response. - Myelodysplastic syndromes with del(5q): decreases transfusion dependence and improves blood counts.

Lenalidomide may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels leading to bleeding tendencies. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require supportive care. - Constipation: difficulty passing stool. - Rash: mild skin irritation or erythema.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Severe neutropenia: markedly low neutrophils with high infection risk. - Severe thrombocytopenia: dangerous bleeding risk. - Secondary primary malignancies: emergence of new cancers. - Severe allergic reactions: anaphylaxis or Stevens‑Johnson syndrome.

Prior to initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for complications. - Monitor blood counts: perform regular CBCs to detect cytopenias early. - Assess thrombotic risk: consider prophylactic anticoagulation in high‑risk patients. - Avoid use in pregnancy: teratogenic potential requires strict contraception. - Adjust for renal impairment: dose modifications may be needed based on creatinine clearance. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Lenalidomide can interact with several drug classes, influencing efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce plasma concentrations. - Live vaccines: increased risk of infection due to immunosuppression. - Anticoagulants (e.g., warfarin): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase exposure. - NSAIDs: additive risk of gastrointestinal bleeding. - Digoxin: potential for altered renal clearance.